<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03173729</url>
  </required_header>
  <id_info>
    <org_study_id>ERC/2017/02/11</org_study_id>
    <nct_id>NCT03173729</nct_id>
  </id_info>
  <brief_title>Point of Care Test to Diagnosed Colorectal Cancer and Polyps in Low Middle Income Countries</brief_title>
  <official_title>Point of Care, Real-time Urine Metabolomics Test to Diagnose Colorectal Cancers and Polyps in Low and Middle Income Countries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Obafemi Awolowo University Teaching Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Obafemi Awolowo University Teaching Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a-two phase study. Phase 1 will adapt a 3-metabolite biosensor that identifies
      patients with colorectal cancer (CRC) and precancerous polyps to Nigerian patients. Phase 2
      will pilot test and evaluate the point-of-care (POC) biosensor device in Nigeria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Phase 1, urine will be collected from 450 Nigerian patients (150 with CRC, 150 with
      polyps, and 150 patients with no colon premalignant or malignant pathology. These samples
      will be used to refine a handheld biosensor. This handheld biosensor is intended to be a
      cost-effective POC diagnostic test highly sensitive for CRC in Nigerian patients.

      In Phase 2, the biosensor device will be piloted in Nigeria with 75 patients that are
      high-risk for CRC.. After the pilot, POC test in real-time analysis on urine from 645
      patients who are in one of three groups: 1.&gt; 40 years of age with rectal bleeding; 2.a family
      history of CRC; 3. have a diagnosis of CRC. All patients will receive a colonoscopy. Beliefs
      and barriers related to urine testing for CRC will be investigated. Study will be completed
      within 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2017</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and specificity of a point of care device to diagnose colorectal cancer and polyps</measure>
    <time_frame>5 years</time_frame>
    <description>We have designed a urine-based point of care diagnostic test to risk-stratify patients at high-risk for colorectal cancer. that will have 50% specificity and 80% sensitivity among Nigerian targeted population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients that are willing to consider continued colorectal cancer surveillance with a urine point of care test.</measure>
    <time_frame>3 years</time_frame>
    <description>The barriers and attitudes of patients towards a point of care urine test will be used to predict how many patients are willing to use this methodology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost per patient of point of care urine test for diagnosing patients with colorectal cancer and polyps.</measure>
    <time_frame>3 years</time_frame>
    <description>The cost per patient will be determined using a cost effectiveness model already developed for the urine screening test in high-income countries.</description>
  </secondary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">1170</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Phase 1 Cohort 1</arm_group_label>
    <description>CRC (n = 150)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 Cohort 2</arm_group_label>
    <description>Precancerous polyps (n = 150)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 Cohort 3</arm_group_label>
    <description>Normal controls (n = 150)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Field Test</arm_group_label>
    <description>75 patients who are high risk for CRC as described in the eligibility</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Validation Study Cohort 1</arm_group_label>
    <description>Family history of CRC (n = 330)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Validation Study Cohort 2</arm_group_label>
    <description>LGI bleeding (n = 240)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Validation Study Cohort 3</arm_group_label>
    <description>Patients with history of CRC (n = 75)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Biosensor Point of Care Device</intervention_name>
    <description>This device is a point of care urine-based metabolomic diagnostic test that detects metabolite biomarkers for CRC and polyps.</description>
    <arm_group_label>Phase 2 Field Test</arm_group_label>
    <arm_group_label>Phase 2 Validation Study Cohort 1</arm_group_label>
    <arm_group_label>Phase 2 Validation Study Cohort 2</arm_group_label>
    <arm_group_label>Phase 2 Validation Study Cohort 3</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      A urine sample is collected with 3 weeks of their surgery or colonoscopy.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients in Phase 1 has a pathologic diagnosis of colon cancer (either by colonoscopy or
        resection specimens), or colonoscopy demonstrating adenomatous polyps or no colon
        premalignant or malignant pathology.

        Patients in Phase 2 are &gt; 40 years of age with LGI bleeding, or at high-risk due to family
        history, or with a history of CRC
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt; 40 years of age with LGI bleeding OR

          -  Patients who are high risk due to family history of CRC

             o Must be at most 10 years younger than when relative presented with CRC (for example,
             a patient with a relative diagnosed at age 40 with CRC will be eligible after age 30)
             OR

          -  Patients with a diagnosis of stage I-III CRC who have no evidence of disease

        Exclusion Criteria:

          -  Patients who are unable to provide written informed consent;

          -  Previous diagnosis, treatment, or surgery for any cancer other than CRC

          -  Age younger than 40 years with no family history of CRC

          -  Any significant medical comorbidities

          -  Inability to provide a urine sample no fewer than 3 days before colonoscopy

          -  Inability to fully complete the patient satisfaction survey tool

          -  Diagnosis of or suspected inflammatory bowel disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olusegun Alatise, MD</last_name>
    <phone>2348033859387</phone>
    <email>segunalatishe@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>T. Peter Kingham, MD</last_name>
    <phone>212-639-5260</phone>
    <email>KinghamT@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Endoscopy Unit, University of Ilorin Teaching Hospital</name>
      <address>
        <city>Ilorin</city>
        <state>Kwara State</state>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ademola A Adeyeye, FWACS</last_name>
      <phone>234 810 101 5373</phone>
      <email>adeyeye_ademola@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Federal Medical Center</name>
      <address>
        <city>Owo</city>
        <state>Ondo State</state>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Abba Katung, FWACS</last_name>
      <phone>234 807 395 7453</phone>
      <email>katungaba@yahoo.co.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Endoscopy Unit, University College Hospital</name>
      <address>
        <city>Ibadan</city>
        <state>Osun State</state>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Omobolaji O Ayandipo, FWACS</last_name>
      <phone>234 805 124 9319</phone>
      <email>yokebukola@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ladoke Akintola University Teaching Hospital</name>
      <address>
        <city>Osogbo</city>
        <state>Osun State</state>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oladapo Kolawole, FWACS</last_name>
      <phone>234 802 385 9166</phone>
      <email>cullerwarley@yahoo.co.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Endoscopy Unit, Obafemi Awolowo University Teaching Hospitals</name>
      <address>
        <city>Ile Ife</city>
        <state>Osun</state>
        <zip>220005</zip>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olusegun I Alatise, FWACS</last_name>
      <phone>2348033859387</phone>
      <email>segunalatishe@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Nigeria</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>May 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2017</study_first_posted>
  <last_update_submitted>May 30, 2017</last_update_submitted>
  <last_update_submitted_qc>May 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Obafemi Awolowo University Teaching Hospital</investigator_affiliation>
    <investigator_full_name>Olusegun Alatise</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Will follow the NIH/NCI approved guidelines</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

